Ulf Petrausch
Papers
1
Total Citations
32
H-Index
1
About
Dr. Ulf Petrausch is a leading oncologist and translational researcher whose work centers on the immunotherapy of genitourinary malignancies, with a particular focus on muscle-invasive urothelial carcinoma (MIUC). His major contributions lie in pioneering perioperative chemoimmunotherapy strategies designed to improve outcomes for patients with high-risk bladder cancer. Dr. Petrausch is the principal investigator of the landmark SAKK 06/17 phase II trial, which investigates the integration of the PD-L1 inhibitor durvalumab with standard cisplatin/gemcitabine chemotherapy before surgery. The preplanned interim analysis of this single-arm trial, which has garnered 32 citations, demonstrated promising efficacy and safety, establishing a critical proof-of-concept for combining checkpoint inhibition with neoadjuvant chemotherapy. This work directly addresses the high relapse rates seen with chemotherapy alone. By spearheading these innovative, practice-informing clinical trials, Dr. Petrausch is at the forefront of reshaping the standard of care for operable bladder cancer, offering patients a potentially more effective, immune-based treatment pathway.
Research Focus
Key Achievements
Top Papers
- 1